Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 21:16:59 Source:styleViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed
Next:Germany's foreign minister visits Kyiv as Ukraine battles to hold off a Russian offensive
You may also like
- Sweden beats France, Britain relegated after losing to Norway at hockey worlds
- New Year Honours: New Zealanders recognised for acting, saving lives, writing hymns and more
- Muhammad Ali's 'Thrilla in Manila' trunks expected to sell for $10m
- Cluster fears over new HK virus cases
- Messi in and Dybala out in Argentina squad for pre
- Ukraine war: Six Russian planes destroyed by drones, says Kyiv
- Lack of reliability with trains sees Auckland commuters opt for the bus
- Coronavirus update: Italy to get aid from Germany, Spain's death rate passes China's
- BBC Countryfile star Adam Henson's wife wrote heartbreaking goodbye letters after cancer diagnosis